Vertex to Participate in Upcoming March Investor Conferences
- Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief Commercial Officer, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026, at 10:00 a.m. ET.
- Susie Lisa, Senior Vice President, Investor Relations, and Miroslava Minkova, Executive Director, Investor Relations, will participate in a fireside chat at the Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 11:30 a.m. ET.
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.
Vertex was founded in 1989 and has its global headquarters in
(VRTX-WEB)
View source version on businesswire.com: https://www.businesswire.com/news/home/20260305227284/en/
Vertex Pharmaceuticals Incorporated
Investors:
InvestorInfo@vrtx.com
Source: Vertex Pharmaceuticals Incorporated
